SANUWAVE Health, an emerging regenerative medicine company, today announced it has signed a two-year exclusive distribution agreement with CAN-med Healthcare of Canada, in which CAN-med will distribute SANUWAVE’s Pulsed Acoustic Cellular Expression (PACE®) technology for acute and chronic wound healing.
CAN-med distributes a wide range of medical offerings, including wound care and trauma products complementary of SANUWAVE’s dermaPACE.
“CAN-med Healthcare is a welcome addition to our growing distribution network for PACE technology, and they have the distinct honor of being the first PACE distributor in North America,” Christopher M. Cashman, president and CEO of SANUWAVE, stated in the press release. “dermaPACE is approved in Canada to treat a wide range of acute and chronic wounds. CAN-med Healthcare’s initial focus will be on the treatment of diabetic foot ulcers, leveraging positive data from our recently completed pivotal clinical trial investigating dermaPACE to treat these debilitating and costly ulcers.
“This collaboration is exciting news for both organizations, and we are equally committed to the hard work ahead of us to reach our ultimate goal of establishing dermaPACE as a first-line wound healing technology with established reimbursement throughout Canada.”
Stephen McDonald, CAN-med’s vice president and general manager, noted the beneficial impact the agreement has on his company and the Canadian healthcare market.
“dermaPACE technology is a great fit for us, as it builds upon our legacy of bringing new, leading edge products to the Canadian market. As a company, we’re always looking for exclusive partnerships that involve innovative, clinically validated and differentiated technology that can improve patient outcomes and overall delivery of care. We believe we’ve met these objectives with SANUWAVE,” McDonald stated.
Jim Ritcey, director of sales and marketing for CAN-med, echoed McDonald’s sentiment.
“It is the mandate of every health department in Canada to improve care to all Canadians, while staying within the confines of increasingly tighter budgets,” Ritcey stated. “We believe that dermaPACE, with its proven safety and efficacy, combined with its potential to reduce costs associated with chronic wound care, could truly be a ‘game changer’ in the battle against chronic wounds.”
For more information visit www.sanuwave.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment